Malignant Hyperthermia
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
Emergency presentation is possibleRapid temperature rise, muscle rigidity, sweating, abnormal heart rhythm or collapse requires emergency treatment.
Breeding advice appliesUse the screening guidance and veterinary or genetics advice before breeding an affected or at-risk animal.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Malignant hyperthermia is an uncommon, life-threatening hypermetabolic crisis of skeletal muscle in a genetically susceptible horse. In Quarter Horse-related lines, a mutation in the RYR1 calcium-release channel can allow uncontrolled calcium movement inside muscle cells. Triggering anaesthetic drugs, intense excitement, heat or exercise then cause sustained contraction and a rapidly accelerating metabolic demand.
During anaesthesia, early clues can include an unexpected rise in exhaled carbon dioxide despite adequate ventilation, rapid heart rate, muscle rigidity and increasing body temperature. Acidosis, high potassium, arrhythmias, sweating, dark urine, unstable blood pressure and disseminated clotting can follow. Temperature elevation may be late, so waiting for extreme fever loses critical time. Exertional episodes can resemble severe tying-up or heatstroke.
Malignant hyperthermia is distinct from ordinary postoperative fever and from HYPP, although horses can inherit both RYR1 and HYPP sodium-channel mutations and signs may overlap. The syndrome is not contagious. A susceptible horse can appear entirely normal between triggers, making a previous unexplained anaesthetic complication or family history especially important.
The crisis can cause kidney failure, pulmonary oedema, muscle necrosis, cardiovascular collapse and death despite treatment. Rapid recognition and immediate dantrolene materially improve the chance of survival. Genetic status also matters before elective anaesthesia and breeding. A horse carrying the recognised mutation should have the diagnosis prominently recorded so every future veterinarian and anaesthetist can avoid triggering agents and prepare an emergency protocol.
A pathogenic RYR1 variant destabilises calcium release inside muscle. Susceptible horses can develop rapidly rising temperature, rigidity, sweating, acidosis and cardiac instability during anaesthesia or intense stress; Quarter Horse lines may carry both MH and PSSM1 variants. This is not ordinary overheating, and the crisis can accelerate despite stopping exercise or inhalant anaesthetic.
Screening & Early Detection
An accredited DNA test on hair roots or blood can identify the recognised equine RYR1 mutation in relevant breeds and families. Testing is appropriate after a compatible crisis, before breeding a relative and before elective anaesthesia when pedigree or prior history raises concern. A negative result for one known variant does not explain every hyperthermic anaesthetic event, so the clinical record remains important.
Before surgery, the team documents breed, family history, previous recoveries, tying-up, HYPP status and all prior anaesthetic problems. Baseline temperature, CK, electrolytes and acid-base values may help but cannot predict an episode in a normal susceptible horse. During anaesthesia, continuous end-tidal carbon dioxide, temperature, heart rhythm and ventilation monitoring support earliest recognition.
Rapidly rising carbon dioxide, rigidity, tachycardia and acidosis trigger the crisis protocol before alternative causes are fully resolved. Anaesthetic-machine malfunction, inadequate ventilation, sepsis, HYPP and ordinary exertional rhabdomyolysis remain differentials. Family members can be offered testing, and positive status should accompany transfer or sale records rather than relying on verbal warning.
Treatment & Management
At the first sign of a crisis, triggering anaesthetic agents are stopped and the procedure ends if safely possible. The horse receives dantrolene, the specific drug that reduces abnormal muscle calcium release. One hundred per cent oxygen with controlled ventilation, active body cooling, intravenous fluids and correction of acidosis and dangerous electrolyte disturbances occur simultaneously. Cooling stops before hypothermia develops.
Heart rhythm, blood pressure, urine output, CK, potassium, blood gases, clotting and kidney values are monitored intensively because complications and recurrence can continue after initial stabilisation. Myoglobin-related kidney injury requires adequate circulation and urine production; treatment is not simply a single dantrolene dose. Recovery from anaesthesia must minimise excitement and muscle activity.
Future procedures use a prepared anaesthetic machine free of volatile trigger contamination, non-triggering intravenous or regional techniques and a calm premedication plan. Dantrolene may be given preventively in selected cases, and an emergency supply must be immediately available. Heat and exercise stress are managed conservatively. A genetically susceptible horse should not be bred without counselling because the variant can be transmitted. Prognosis is guarded once severe hyperthermia, arrhythmia or organ failure occurs.
Breeds or species affected
American Quarter Horse
Open horse breed description, care requirements and conditions
American Paint Horse
Open horse breed description, care requirements and conditions
Appaloosa
Open horse breed description, care requirements and conditions
Quarter Pony
Open horse breed description, care requirements and conditions